Replimune Group (NASDAQ:REPL) Stock Price Down 8% – Here’s What Happened

Shares of Replimune Group, Inc. (NASDAQ:REPL) fell 8% on Friday . The company traded as low as $6.96 and last traded at $6.9730. 1,024,169 shares were traded during trading, a decline of 25% from the average session volume of 1,369,877 shares. The stock had previously closed at $7.58.

Wall Street Analyst Weigh In

A number of equities analysts have commented on REPL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Piper Sandler raised their target price on Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Finally, Wedbush lifted their price target on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.00.

Replimune Group Trading Down 5.8%

The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average is $7.73 and its two-hundred day moving average is $7.67. The firm has a market cap of $589.55 million, a price-to-earnings ratio of -2.08 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. Equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently made changes to their positions in the company. International Assets Investment Management LLC bought a new position in Replimune Group in the fourth quarter valued at about $29,000. CWM LLC raised its holdings in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Replimune Group by 37.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares during the period. Raymond James Financial Inc. acquired a new position in Replimune Group during the 2nd quarter valued at about $69,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.